Del buys X-Ray Technologies
Del Global Technologies has acquired X-Ray Technologies, a developer of low-cost x-ray systems for the private-office, veterinary, and chiropractic markets. Del has integrated its purchase into its Universal product line to form a new division,
Del Global Technologies has acquired X-Ray Technologies, a developer of low-cost x-ray systems for the private-office, veterinary, and chiropractic markets. Del has integrated its purchase into its Universal product line to form a new division, Universal/X-Tek, that will sell products under the Universal and X-Tek trade names.
X-Ray Technologies was founded in 1994 and began selling systems in 1996. The company's products include lightweight full-body x-ray systems that sell in the range of $10,000 to $15,000, making them cost-effective for smaller medical facilities, according to Leonard Trugman, Del chairman, CEO, and president. X-Ray Technologies had revenues of over $1 million last year, Trugman said.
Del believes it can boost sales of the X-Ray Technologies product line by plugging the systems into the Del distribution network. Del is especially enthusiastic about the potential of the systems in international markets, such as in developing countries.
As part of the acquisition, X-Ray Technologies president and founder Randy Duffy will be general manager of the Universal/X-Tek division, reporting to John Mankowich, vice president and general manager of Del's Gendex-Del Medical Imaging subsidiary.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
